These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29088328)

  • 1. Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease.
    Collet JP; Roffi M; Byrne RA; Costa F; Valgimigli M; ; ;
    Eur Heart J; 2018 Jan; 39(3):e1-e33. PubMed ID: 29088328
    [No Abstract]   [Full Text] [Related]  

  • 2. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.].
    Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Peticevic M; Roffi M; Steg PG; Windecker S; Zamorano JL
    Kardiol Pol; 2017; 75(12):1217-1299. PubMed ID: 29251754
    [No Abstract]   [Full Text] [Related]  

  • 3. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
    Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Petricevic M; Roffi M; Steg PG; Windecker S; Zamorano JL; Levine GN; ; ;
    Eur Heart J; 2018 Jan; 39(3):213-260. PubMed ID: 28886622
    [No Abstract]   [Full Text] [Related]  

  • 4. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: What is new?].
    Öngen Z
    Turk Kardiyol Dern Ars; 2018 Jan; 46(1):1-6. PubMed ID: 29339684
    [No Abstract]   [Full Text] [Related]  

  • 5. Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease.
    Mauri L; Smith SC
    JAMA Cardiol; 2016 Sep; 1(6):733-4. PubMed ID: 27548911
    [No Abstract]   [Full Text] [Related]  

  • 6. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
    Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Petricevic M; Roffi M; Steg PG; Windecker S; Zamorano JL; Levine GN;
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):34-78. PubMed ID: 29045581
    [No Abstract]   [Full Text] [Related]  

  • 7. Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease-a review.
    Alber HF; Huber K
    Wien Klin Wochenschr; 2018 Dec; 130(23-24):694-697. PubMed ID: 30030604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of antiplatelet therapy in patients who require anticoagulation.
    Henkel DM; Holmes DR
    J Invasive Cardiol; 2009 Apr; 21(4):186-9. PubMed ID: 19342758
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
    Behan MW; Chew DP; Aylward PE
    Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
    Terpening C
    J Am Board Fam Med; 2009; 22(1):51-6. PubMed ID: 19124633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.
    Ignjatovic V; Pavlovic S; Miloradovic V; Andjelkovic N; Davidovic G; Djurdjevic P; Stolic R; Iric-Cupic V; Simic I; Ignjatovic VD; Petrovic N; Smiljanic Z; Zdravkovic V; Simovic S; Jovanovic D; Nesic J
    J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):44-52. PubMed ID: 25868659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].
    Degrauwe S; Iglesias JF
    Rev Med Suisse; 2016 May; 12(520):1022-6, 1028-34. PubMed ID: 27424342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin in coronary artery disease: an appraisal of functions and limitations.
    Würtz M
    Dan Med J; 2015 Apr; 62(4):B5011. PubMed ID: 25872543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous chest wall hematoma with dual antiplatelet therapy.
    Bevan P; Menon A; Bunton R
    Can J Cardiol; 2014 Feb; 30(2):247.e1-2. PubMed ID: 24290862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern antiplatelet agents in coronary artery disease.
    Power RF; Hynes BG; Moran D; Yagoub H; Kiernan G; Ruggiero NJ; Kiernan TJ
    Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1261-72. PubMed ID: 23190065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates in antiplatelet agents used in cardiovascular diseases.
    Cheng JW
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.